Skip to main content
. 2009 Jan;63(1):27–34. doi: 10.1111/j.1742-1241.2008.01947.x

Table 3.

Summary of select comorbidities and previous PDE5 use at baseline (safety population, N=191)

Comorbidities, n (%)
Hypertension 61 (32)
Hypercholesterolaemia 26 (14)
Depression 26 (14)
Hyperlipidaemia 20 (10)
Diabetes 13 (7)
Prior PDE5 inhibitor use, n (%)
Sildenafil 131 (69)
Tadalafil 37 (19)
Vardenafil 46 (24)

PDE5, phosphodiesterase type 5.